Vertex Pharmaceuticals (NQ:VRTX)

493.64 -13.36 (-2.63%)

Delayed Quote Updated: 11:32 AM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

June 29, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals...

Via Benzinga

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 27, 2026

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Via The Motley Fool

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗

June 23, 2026

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Via MarketBeat

Topics ETFs

Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗

June 23, 2026

Via Chartmill

VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗

June 01, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗

May 28, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗

May 05, 2026

Via Chartmill

The Best Stocks to Invest $1,000 in Right Now ↗

June 22, 2026

Exploring some of the top bargains in a multi-trillion-dollar industry.

Via The Motley Fool

3 of Wall Street’s Favorite Stocks to Consider Right Now

June 22, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

2 Reasons to Like VRTX (and 1 Not So Much)

June 22, 2026

Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell s...

Via StockStory

If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗

June 20, 2026

These well-established companies are on track to deliver more growth.

Via The Motley Fool

Topics Intellectual Property

Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗

June 20, 2026

These companies don't typically compete directly with one another, but that might change soon.

Via The Motley Fool

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗

June 18, 2026

The opportunity is enormous, but uncertainty remains.

Via The Motley Fool

3 Market-Beating Stocks Worth Investigating

June 18, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

They have at least one thing in common: An exciting pipeline.

Via The Motley Fool

Topics ETFs

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

June 11, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗

June 08, 2026

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.

Via The Motley Fool

CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗

June 08, 2026

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Via The Motley Fool

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

June 05, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Best Stocks to Invest $500 in Right Now ↗

June 04, 2026

The market is underestimating these companies' long-term prospects.

Via The Motley Fool

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

June 03, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

June 01, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

May 29, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...

Via StockStory

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

Which S&P500 stocks are moving on Tuesday? ↗

May 12, 2026

Via Chartmill

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗

May 11, 2026

The biotech's innovative platform could pay off.

Via The Motley Fool

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

May 11, 2026

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi...

Via StockStory

Topics Earnings

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 06, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗

May 06, 2026

The market wasn't impressed by its latest quarterly update.

Via The Motley Fool

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.